| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 28 | 2022 | 76 | 2.490 |
Why?
|
| Prenatal Exposure Delayed Effects | 26 | 2019 | 168 | 2.160 |
Why?
|
| Multiple Sclerosis | 16 | 2019 | 102 | 1.690 |
Why?
|
| Bipolar Disorder | 9 | 2022 | 58 | 1.680 |
Why?
|
| Polymorphism, Single Nucleotide | 27 | 2020 | 363 | 1.490 |
Why?
|
| Genetic Predisposition to Disease | 23 | 2022 | 372 | 1.470 |
Why?
|
| Phenytoin | 2 | 2020 | 4 | 1.320 |
Why?
|
| Cytochrome P-450 CYP2C9 | 2 | 2020 | 5 | 1.320 |
Why?
|
| Genome-Wide Association Study | 23 | 2022 | 248 | 1.190 |
Why?
|
| Humans | 94 | 2022 | 17376 | 0.900 |
Why?
|
| Male | 66 | 2020 | 9843 | 0.860 |
Why?
|
| Female | 74 | 2020 | 12444 | 0.850 |
Why?
|
| Cognition Disorders | 3 | 2014 | 30 | 0.840 |
Why?
|
| Pharmacogenomic Variants | 2 | 2020 | 7 | 0.820 |
Why?
|
| Genetic Loci | 8 | 2020 | 54 | 0.800 |
Why?
|
| Adult | 59 | 2020 | 7529 | 0.790 |
Why?
|
| Risk Factors | 37 | 2020 | 3255 | 0.750 |
Why?
|
| HLA-DRB1 Chains | 8 | 2019 | 12 | 0.720 |
Why?
|
| Pregnancy | 33 | 2019 | 1466 | 0.700 |
Why?
|
| Cytochrome P-450 CYP2C19 | 1 | 2020 | 4 | 0.680 |
Why?
|
| Drug Eruptions | 1 | 2020 | 4 | 0.680 |
Why?
|
| Prostatic Neoplasms | 6 | 2020 | 263 | 0.620 |
Why?
|
| Cohort Studies | 33 | 2020 | 2526 | 0.600 |
Why?
|
| Middle Aged | 34 | 2020 | 7885 | 0.590 |
Why?
|
| Body Mass Index | 9 | 2018 | 937 | 0.570 |
Why?
|
| Child of Impaired Parents | 5 | 2013 | 26 | 0.570 |
Why?
|
| Ethnic Groups | 10 | 2020 | 456 | 0.540 |
Why?
|
| Case-Control Studies | 21 | 2018 | 1100 | 0.530 |
Why?
|
| Pregnancy Complications, Infectious | 8 | 2016 | 151 | 0.520 |
Why?
|
| Toxoplasmosis | 3 | 2016 | 4 | 0.510 |
Why?
|
| Paternal Age | 3 | 2013 | 9 | 0.490 |
Why?
|
| Aged | 25 | 2020 | 6129 | 0.490 |
Why?
|
| European Continental Ancestry Group | 12 | 2020 | 480 | 0.480 |
Why?
|
| Influenza, Human | 5 | 2016 | 282 | 0.480 |
Why?
|
| Oxytocics | 1 | 2014 | 2 | 0.460 |
Why?
|
| Oxytocin | 1 | 2014 | 4 | 0.460 |
Why?
|
| Glaucoma | 3 | 2020 | 12 | 0.430 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 1942 | 0.410 |
Why?
|
| Pregnancy Complications | 3 | 2012 | 197 | 0.400 |
Why?
|
| Smoking | 4 | 2017 | 428 | 0.390 |
Why?
|
| Young Adult | 15 | 2019 | 2473 | 0.380 |
Why?
|
| Depressive Disorder, Major | 2 | 2018 | 100 | 0.370 |
Why?
|
| Multifactorial Inheritance | 3 | 2020 | 21 | 0.360 |
Why?
|
| Aging | 4 | 2016 | 160 | 0.360 |
Why?
|
| Health | 3 | 2015 | 32 | 0.360 |
Why?
|
| Alleles | 7 | 2020 | 80 | 0.350 |
Why?
|
| Pharmacogenomic Testing | 2 | 2020 | 4 | 0.330 |
Why?
|
| Prospective Studies | 12 | 2014 | 1229 | 0.330 |
Why?
|
| Hispanic Americans | 5 | 2020 | 378 | 0.320 |
Why?
|
| Septum Pellucidum | 1 | 2009 | 1 | 0.310 |
Why?
|
| Communicable Diseases | 1 | 2009 | 15 | 0.310 |
Why?
|
| Immunoglobulin G | 5 | 2016 | 29 | 0.300 |
Why?
|
| Genomics | 4 | 2020 | 56 | 0.300 |
Why?
|
| Retrospective Studies | 8 | 2020 | 2428 | 0.300 |
Why?
|
| Maternal Exposure | 6 | 2016 | 66 | 0.290 |
Why?
|
| Mutation | 4 | 2018 | 132 | 0.290 |
Why?
|
| Computational Biology | 3 | 2020 | 26 | 0.280 |
Why?
|
| Genotype | 10 | 2017 | 223 | 0.280 |
Why?
|
| Adolescent | 17 | 2019 | 3533 | 0.280 |
Why?
|
| Blood Pressure | 2 | 2020 | 275 | 0.270 |
Why?
|
| Molecular Epidemiology | 4 | 2020 | 44 | 0.260 |
Why?
|
| Electronic Health Records | 4 | 2022 | 707 | 0.260 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2005 | 2 | 0.250 |
Why?
|
| Tobacco Smoke Pollution | 3 | 2014 | 33 | 0.250 |
Why?
|
| Quantitative Trait Loci | 3 | 2020 | 38 | 0.240 |
Why?
|
| Macular Degeneration | 2 | 2016 | 20 | 0.240 |
Why?
|
| Social Class | 2 | 2017 | 117 | 0.240 |
Why?
|
| Genotyping Techniques | 2 | 2015 | 26 | 0.230 |
Why?
|
| Treatment Outcome | 3 | 2019 | 1170 | 0.230 |
Why?
|
| Cognition | 2 | 2016 | 81 | 0.230 |
Why?
|
| HLA-A2 Antigen | 2 | 2014 | 2 | 0.230 |
Why?
|
| California | 13 | 2019 | 2317 | 0.220 |
Why?
|
| Intraocular Pressure | 3 | 2018 | 11 | 0.210 |
Why?
|
| Risk Assessment | 5 | 2020 | 1079 | 0.200 |
Why?
|
| Phenotype | 6 | 2019 | 148 | 0.190 |
Why?
|
| Transcription Factors | 2 | 2019 | 19 | 0.190 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2017 | 87 | 0.190 |
Why?
|
| Toxoplasma | 2 | 2016 | 3 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 120 | 0.190 |
Why?
|
| Adult Children | 2 | 2012 | 8 | 0.190 |
Why?
|
| Genetic Background | 1 | 2020 | 2 | 0.180 |
Why?
|
| Skin Pigmentation | 1 | 2020 | 6 | 0.180 |
Why?
|
| African Americans | 5 | 2019 | 443 | 0.180 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 2 | 0.170 |
Why?
|
| Cornea | 1 | 2020 | 3 | 0.170 |
Why?
|
| Corneal Diseases | 1 | 2020 | 3 | 0.170 |
Why?
|
| Breast Density | 1 | 2020 | 31 | 0.170 |
Why?
|
| HLA-B15 Antigen | 1 | 2020 | 2 | 0.170 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 165 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 56 | 0.170 |
Why?
|
| Maternal Welfare | 1 | 2000 | 12 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 58 | 0.160 |
Why?
|
| Age Factors | 5 | 2014 | 884 | 0.160 |
Why?
|
| Exome | 2 | 2022 | 21 | 0.160 |
Why?
|
| HLA-A Antigens | 2 | 2017 | 2 | 0.160 |
Why?
|
| Pregnancy Trimesters | 3 | 2016 | 29 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2020 | 52 | 0.160 |
Why?
|
| Hydrocortisone | 1 | 2019 | 18 | 0.160 |
Why?
|
| Fetal Development | 1 | 2019 | 14 | 0.160 |
Why?
|
| Sweden | 5 | 2017 | 19 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2019 | 17 | 0.160 |
Why?
|
| Mendelian Randomization Analysis | 4 | 2020 | 26 | 0.150 |
Why?
|
| Child | 6 | 2019 | 2382 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 145 | 0.150 |
Why?
|
| Intelligence Tests | 2 | 2016 | 3 | 0.150 |
Why?
|
| Sex Factors | 5 | 2019 | 607 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 977 | 0.150 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2018 | 10 | 0.150 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2016 | 13 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 24 | 0.140 |
Why?
|
| Behavior | 1 | 2017 | 17 | 0.140 |
Why?
|
| Datasets as Topic | 1 | 2017 | 20 | 0.140 |
Why?
|
| Anthropometry | 1 | 2017 | 60 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2017 | 77 | 0.140 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2017 | 27 | 0.140 |
Why?
|
| Interleukin-8 | 2 | 2010 | 4 | 0.140 |
Why?
|
| Environmental Exposure | 1 | 2018 | 119 | 0.140 |
Why?
|
| Prevalence | 7 | 2016 | 839 | 0.140 |
Why?
|
| Exonucleases | 1 | 2016 | 1 | 0.130 |
Why?
|
| Presbycusis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 311 | 0.130 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 6 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 3 | 0.130 |
Why?
|
| Trans-Activators | 1 | 2016 | 9 | 0.130 |
Why?
|
| Major Histocompatibility Complex | 2 | 2013 | 3 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 76 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2019 | 239 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 62 | 0.130 |
Why?
|
| Hearing Loss | 1 | 2016 | 18 | 0.130 |
Why?
|
| Prenatal Care | 2 | 2016 | 127 | 0.130 |
Why?
|
| Vitamin D | 1 | 2017 | 72 | 0.130 |
Why?
|
| Drinking | 1 | 2016 | 3 | 0.130 |
Why?
|
| Coffee | 1 | 2016 | 5 | 0.130 |
Why?
|
| Stress, Psychological | 2 | 2015 | 133 | 0.130 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2016 | 2 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2016 | 21 | 0.120 |
Why?
|
| Pediatric Obesity | 2 | 2014 | 86 | 0.120 |
Why?
|
| Refraction, Ocular | 1 | 2015 | 2 | 0.120 |
Why?
|
| Refractive Errors | 1 | 2015 | 7 | 0.120 |
Why?
|
| Biomarkers | 5 | 2019 | 306 | 0.120 |
Why?
|
| Bereavement | 1 | 1995 | 5 | 0.120 |
Why?
|
| Hyperuricemia | 1 | 2015 | 2 | 0.120 |
Why?
|
| Telomere | 1 | 2015 | 18 | 0.120 |
Why?
|
| Allopurinol | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2015 | 2 | 0.120 |
Why?
|
| Maternal Age | 4 | 2009 | 74 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 10 | 0.120 |
Why?
|
| Gene Frequency | 4 | 2017 | 39 | 0.120 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 10 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 16 | 0.120 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 1 | 0.120 |
Why?
|
| Aquaporin 4 | 1 | 2014 | 2 | 0.120 |
Why?
|
| Family | 1 | 2015 | 106 | 0.120 |
Why?
|
| Social Environment | 1 | 1995 | 85 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 11 | 0.120 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2014 | 10 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 4 | 0.110 |
Why?
|
| Mortality | 1 | 1995 | 116 | 0.110 |
Why?
|
| Proportional Hazards Models | 6 | 2013 | 702 | 0.110 |
Why?
|
| Psychotic Disorders | 3 | 2011 | 49 | 0.110 |
Why?
|
| Body Size | 1 | 2014 | 31 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 355 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 1287 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 537 | 0.110 |
Why?
|
| Infant, Newborn | 6 | 2016 | 805 | 0.100 |
Why?
|
| Continental Population Groups | 1 | 2015 | 289 | 0.100 |
Why?
|
| Alcoholism | 1 | 2017 | 337 | 0.100 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2012 | 26 | 0.100 |
Why?
|
| Poverty | 1 | 2014 | 165 | 0.100 |
Why?
|
| Gene-Environment Interaction | 3 | 2018 | 20 | 0.100 |
Why?
|
| Risk | 4 | 2017 | 498 | 0.100 |
Why?
|
| Neuropsychological Tests | 2 | 2010 | 43 | 0.100 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 12 | 0.100 |
Why?
|
| Dementia, Vascular | 1 | 2012 | 4 | 0.100 |
Why?
|
| Vitamin A Deficiency | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hypertension | 1 | 2016 | 469 | 0.100 |
Why?
|
| Haplotypes | 3 | 2019 | 34 | 0.100 |
Why?
|
| Genital Diseases, Female | 2 | 2009 | 9 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 102 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2011 | 5 | 0.090 |
Why?
|
| Antibodies, Protozoan | 2 | 2016 | 3 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 121 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2012 | 49 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 1155 | 0.090 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 6 | 0.090 |
Why?
|
| Prenatal Diagnosis | 3 | 2010 | 17 | 0.090 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2011 | 2 | 0.090 |
Why?
|
| Bariatric Surgery | 1 | 2013 | 131 | 0.090 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 7 | 0.090 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 1 | 0.090 |
Why?
|
| Schizophrenic Psychology | 1 | 2010 | 5 | 0.080 |
Why?
|
| Brain | 1 | 2010 | 48 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2015 | 367 | 0.080 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2007 | 13 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2008 | 6 | 0.080 |
Why?
|
| Somatomedins | 1 | 2008 | 5 | 0.080 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2008 | 5 | 0.080 |
Why?
|
| Infant | 4 | 2016 | 1162 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2020 | 32 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 4 | 2014 | 19 | 0.070 |
Why?
|
| Genome, Human | 3 | 2014 | 34 | 0.070 |
Why?
|
| Craniofacial Abnormalities | 1 | 2008 | 7 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 19 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 37 | 0.070 |
Why?
|
| Gene Expression | 2 | 2018 | 23 | 0.070 |
Why?
|
| Time Factors | 3 | 2019 | 1044 | 0.070 |
Why?
|
| Obesity | 1 | 2014 | 814 | 0.070 |
Why?
|
| Antibodies, Viral | 2 | 2006 | 66 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 487 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2020 | 38 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 439 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 16 | 0.070 |
Why?
|
| Homocysteine | 1 | 2007 | 11 | 0.070 |
Why?
|
| Herpesvirus 2, Human | 1 | 2006 | 3 | 0.070 |
Why?
|
| Herpes Simplex | 1 | 2006 | 7 | 0.070 |
Why?
|
| Research Design | 4 | 2016 | 343 | 0.070 |
Why?
|
| Logistic Models | 3 | 2014 | 884 | 0.070 |
Why?
|
| Animals | 3 | 2018 | 280 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2016 | 1375 | 0.060 |
Why?
|
| Pregnancy, Unwanted | 1 | 2006 | 7 | 0.060 |
Why?
|
| Blood Group Incompatibility | 1 | 2005 | 1 | 0.060 |
Why?
|
| Protective Factors | 2 | 2016 | 32 | 0.060 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2005 | 4 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2014 | 644 | 0.060 |
Why?
|
| Linkage Disequilibrium | 2 | 2016 | 28 | 0.060 |
Why?
|
| State Health Plans | 1 | 2005 | 33 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2005 | 26 | 0.060 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 1 | 0.060 |
Why?
|
| Prognosis | 2 | 2020 | 604 | 0.060 |
Why?
|
| Chromosome Mapping | 2 | 2013 | 18 | 0.050 |
Why?
|
| Depression, Postpartum | 1 | 2004 | 22 | 0.050 |
Why?
|
| Cytokines | 2 | 2016 | 30 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 2 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 4 | 0.050 |
Why?
|
| Anxiety | 1 | 2004 | 154 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 46 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 31 | 0.050 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2022 | 8 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2016 | 25 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 14 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Educational Status | 2 | 2006 | 179 | 0.040 |
Why?
|
| United States | 3 | 2017 | 3891 | 0.040 |
Why?
|
| Aorta | 1 | 2020 | 3 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2020 | 4 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 8 | 0.040 |
Why?
|
| Chromatin | 1 | 2020 | 5 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 22 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 11 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 380 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 52 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 104 | 0.040 |
Why?
|
| Incidence | 3 | 2015 | 1266 | 0.040 |
Why?
|
| Binding Sites | 1 | 2019 | 2 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2000 | 51 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 9 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2019 | 34 | 0.040 |
Why?
|
| Mammography | 1 | 2020 | 168 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 35 | 0.040 |
Why?
|
| HLA-A3 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| HLA-B7 Antigen | 1 | 2019 | 3 | 0.040 |
Why?
|
| LIM-Homeodomain Proteins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 5 | 0.040 |
Why?
|
| Pesticides | 1 | 2018 | 8 | 0.040 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1287 | 0.040 |
Why?
|
| Proteins | 1 | 2018 | 15 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 20 | 0.040 |
Why?
|
| United Kingdom | 1 | 2018 | 25 | 0.040 |
Why?
|
| Mice | 1 | 2018 | 80 | 0.040 |
Why?
|
| Asian Americans | 1 | 2019 | 164 | 0.040 |
Why?
|
| Machine Learning | 1 | 2018 | 53 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 4 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2017 | 5 | 0.030 |
Why?
|
| Body Weight | 1 | 2018 | 203 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 70 | 0.030 |
Why?
|
| Prostate | 1 | 2017 | 28 | 0.030 |
Why?
|
| Eating | 1 | 1996 | 34 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 50 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cystic Fibrosis | 1 | 1996 | 6 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2017 | 144 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 1996 | 16 | 0.030 |
Why?
|
| Work | 1 | 2015 | 10 | 0.030 |
Why?
|
| Mothers | 2 | 2007 | 103 | 0.030 |
Why?
|
| Genetic Testing | 1 | 1996 | 70 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pregnant Women | 1 | 1996 | 46 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 54 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 25 | 0.030 |
Why?
|
| Self Report | 1 | 2017 | 257 | 0.030 |
Why?
|
| Comorbidity | 2 | 2008 | 564 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 42 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2015 | 2 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 5 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 9 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 63 | 0.030 |
Why?
|
| Uric Acid | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 11 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 1996 | 154 | 0.030 |
Why?
|
| Weight Gain | 1 | 1996 | 156 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 15 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 66 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 18 | 0.030 |
Why?
|
| Optic Neuritis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Myelitis, Transverse | 1 | 2014 | 4 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 2016 | 309 | 0.030 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2014 | 1 | 0.030 |
Why?
|
| Arabidopsis Proteins | 1 | 2014 | 1 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2014 | 2 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 677 | 0.030 |
Why?
|
| HLA-DP beta-Chains | 1 | 2013 | 1 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 2 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 7 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 8 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2013 | 11 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2013 | 11 | 0.030 |
Why?
|
| Models, Biological | 1 | 2013 | 28 | 0.030 |
Why?
|
| Gestational Age | 1 | 2013 | 112 | 0.030 |
Why?
|
| Mental Disorders | 2 | 2006 | 273 | 0.020 |
Why?
|
| Informed Consent | 1 | 2012 | 19 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 6 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2011 | 1 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 2 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 27 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 46 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 140 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 178 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 145 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 211 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 11 | 0.020 |
Why?
|
| Health Status | 1 | 2012 | 295 | 0.020 |
Why?
|
| Life Change Events | 1 | 2010 | 31 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 226 | 0.020 |
Why?
|
| Health Behavior | 1 | 2012 | 345 | 0.020 |
Why?
|
| Bias | 2 | 2000 | 100 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 52 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 3 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 8 | 0.020 |
Why?
|
| Hemoglobinometry | 1 | 2008 | 3 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 538 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2008 | 29 | 0.020 |
Why?
|
| Infant, Premature, Diseases | 1 | 2008 | 16 | 0.020 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2008 | 54 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 244 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 805 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2004 | 366 | 0.020 |
Why?
|
| Informatics | 1 | 2007 | 2 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2007 | 12 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 22 | 0.020 |
Why?
|
| Parity | 1 | 2007 | 57 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 72 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 4 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 11 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2007 | 17 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 22 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 24 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2007 | 41 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2006 | 22 | 0.020 |
Why?
|
| Infection | 1 | 2006 | 17 | 0.020 |
Why?
|
| Demography | 1 | 2006 | 96 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 14 | 0.020 |
Why?
|
| Maternal Behavior | 1 | 2005 | 12 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2007 | 148 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 609 | 0.010 |
Why?
|
| Influenza A virus | 1 | 2004 | 13 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 27 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2005 | 64 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2003 | 8 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 23 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 52 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 304 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2004 | 142 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2004 | 306 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 424 | 0.010 |
Why?
|
| Health Maintenance Organizations | 1 | 2004 | 408 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 448 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 280 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 533 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2002 | 173 | 0.010 |
Why?
|
| Registries | 1 | 2000 | 460 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1996 | 28 | 0.010 |
Why?
|
| Dietary Sucrose | 1 | 1996 | 13 | 0.010 |
Why?
|
| Diet Records | 1 | 1996 | 37 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1996 | 48 | 0.010 |
Why?
|
| Energy Intake | 1 | 1996 | 98 | 0.010 |
Why?
|
| Dietary Fats | 1 | 1996 | 89 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1996 | 4 | 0.010 |
Why?
|
| Linear Models | 1 | 1996 | 210 | 0.010 |
Why?
|
| Comprehension | 1 | 1996 | 18 | 0.010 |
Why?
|